ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1345

Association of HLA-DRB1*0301 with Antisynthetase Syndrome in Spanish Patients

Raquel Lopez-Mejías1, Sara Remuzgo-Martínez1, Fernanda Genre1, Verónica Pulito-Cueto1, Norberto Ortego Centeno2, Eva Perez Pampín3, Antonio Mera3, Julia Martínez-Barrio4, Francisco Javier López Longo4, Verónica Mijares1, Leticia Lera-Gomez1, Sonia Fernández Rozas1, Victor Mora Cuesta5, David Iturbe Fernández1, Jose Manuel Cifrian Martinez1, Fredeswinda Romero Bueno6, Olga Sanchez-Pernaute6, Ricardo Blanco1, Laura Riesco-Dávila7, Laura Nuño8, María Gema Bonilla Hernán9, Alejandro Balsa9, Ernesto Trallero-Araguás10, Albert Selva O'Callaghan10, Javier Martin11, Javier Llorca12, Santos Castañeda13, Javier Gonzalo Ocejo7, Lorenzo Cavagna14 and Miguel Angel González-Gay1,15,16, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, 3Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 4Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 5Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santender, Spain, 6Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 7Immunology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 8Rheumatology, Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 9Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 10Rheumatology Department. Hospital Universitario Vall d´Hebron, Barcelona, Spain, 11Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain., Granada, Spain, 12Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, 13Rheumatology, Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 14Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 15School of Medicine, University of Cantabria, Santander, Spain, 16Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: human leukocyte antigens (HLA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Antisynthetase syndrome (ASSD) is an inflammatory connective tissue disease characterized by the classic triad: arthritis, myositis, and interstitial lung disease (ILD) [1-3]. Raynaud’s phenomenon, mechanic’s hands, and fever are other relevant but less prevalent clinical findings observed in this condition [1, 3, 4]. The pathophysiology of ASSD is not entirely understood, but genetic predisposition, viral infections and medication use may play a role in the development of this disease [5]. In this regard, the human leucocyte antigen (HLA) region has been described as a genetic factor involved in ASSD in different populations. Taking all these considerations into account, the main objective of our study was to evaluate the potential influence of the HLA region in the susceptibility of ASSD in a cohort of patients from Spain.

Methods: Our study population included 83 Spanish patients diagnosed with ASSD and 303 sex and ethnically matched controls. Patients were recruited from Hospital Universitario Marqués de Valdecilla (Santander), Hospital Clínico San Cecilio (Granada), Complejo Hospitalario Universitario de Santiago (Santiago de Compostela), Hospital General Vall d’Hebron (Barcelona) and Hospital Universitario La Princesa, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario La Paz and Hospital General Universitario Gregorio Marañón (Madrid). HLA–DRB1 alleles were determined using the polymerase chain reaction–sequence-specific oligonucleotide probe method.

Results: HLA-DRB1*03 was significantly increased in patients with ASSD compared to controls (53.0% versus 18.2%, p<0.01, odds ratio=5.09 [95% confidence interval: 2.92-8.84]). Specifically, the susceptibility effect of HLA-DRB1*03 was due to the HLA-DRB1*0301 allele.

Conclusion: Our study suggests that the HLA-DRB1*0301 allele is associated with the susceptibility to ASSD in Spanish patients.

[1] Medicine (Baltimore) 2015;94:e1144; [2] Clin Exp Rheumatol 2018;36:44-9; [3] Joint Bone Spine 2003;70:161–8; [4] Autoimmun Rev 2014;13:883–91; [5] Curr Med Chem 2015;22:1963-75.

RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, “Investing in your future”) (grant CP16/00033). FG is a recipient of a Sara Borrell post-doctoral fellowship from the ISCIII, co-funded by the ESF (grant CD15/00095). SR-M is supported by funds of the RETICS Program (RD16/0012/0009), co-funded by the European Regional Development Fund, ERDF. VP-C is supported by funds of IDIVAL (PREVAL18/01). VM is supported by funds of a Miguel Servet type I programme (CP16/00033) (ISCIII, co-funded by ERDF).


Disclosure: R. Lopez-Mejías, None; S. Remuzgo-Martínez, None; F. Genre, None; V. Pulito-Cueto, None; N. Ortego Centeno, None; E. Perez Pampín, None; A. Mera, None; J. Martínez-Barrio, None; F. J. López Longo, None; V. Mijares, None; L. Lera-Gomez, None; S. Fernández Rozas, None; V. Mora Cuesta, None; D. Iturbe Fernández, None; J. M. Cifrian Martinez, None; F. Romero Bueno, None; O. Sanchez-Pernaute, None; R. Blanco, None; L. Riesco-Dávila, None; L. Nuño, None; M. G. Bonilla Hernán, None; A. Balsa, None; E. Trallero-Araguás, None; A. Selva O'Callaghan, None; J. Martin, None; J. Llorca, None; S. Castañeda, None; J. G. Ocejo, None; L. Cavagna, None; M. A. González-Gay, None.

To cite this abstract in AMA style:

Lopez-Mejías R, Remuzgo-Martínez S, Genre F, Pulito-Cueto V, Ortego Centeno N, Perez Pampín E, Mera A, Martínez-Barrio J, López Longo FJ, Mijares V, Lera-Gomez L, Fernández Rozas S, Mora Cuesta V, Iturbe Fernández D, Cifrian Martinez JM, Romero Bueno F, Sanchez-Pernaute O, Blanco R, Riesco-Dávila L, Nuño L, Bonilla Hernán MG, Balsa A, Trallero-Araguás E, Selva O'Callaghan A, Martin J, Llorca J, Castañeda S, Ocejo JG, Cavagna L, González-Gay MA. Association of HLA-DRB1*0301 with Antisynthetase Syndrome in Spanish Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/association-of-hla-drb10301-with-antisynthetase-syndrome-in-spanish-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-hla-drb10301-with-antisynthetase-syndrome-in-spanish-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology